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Summary
Background Suspected acute coronary syndrome is the commonest reason for emergency admission to hospital and 
is a large burden on health-care resources. Strategies to identify low-risk patients suitable for immediate discharge 
would have major benefi ts.
Methods We did a prospective cohort study of 6304 consecutively enrolled patients with suspected acute coronary 
syndrome presenting to four secondary and tertiary care hospitals in Scotland. We measured plasma troponin 
concentrations at presentation using a high-sensitivity cardiac troponin I assay. In derivation and validation cohorts, 
we evaluated the negative predictive value of a range of troponin concentrations for the primary outcome of index 
myocardial infarction, or subsequent myocardial infarction or cardiac death at 30 days. This trial is registered with 
ClinicalTrials.gov (number NCT01852123).
Findings 782 (16%) of 4870 patients in the derivation cohort had index myocardial infarction, with a further 32 (1%) 
re-presenting with myocardial infarction and 75 (2%) cardiac deaths at 30 days. In patients without myocardial 
infarction at presentation, troponin concentrations were less than 5 ng/L in 2311 (61%) of 3799 patients, with a 
negative predictive value of 99·6% (95% CI 99·3–99·8) for the primary outcome. The negative predictive value was 
consistent across groups stratifi ed by age, sex, risk factors, and previous cardiovascular disease. In two independent 
validation cohorts, troponin concentrations were less than 5 ng/L in 594 (56%) of 1061 patients, with an overall 
negative predictive value of 99·4% (98·8–99·9). At 1 year, these patients had a lower risk of myocardial infarction and 
cardiac death than did those with a troponin concentration of 5 ng/L or more (0·6% vs 3·3%; adjusted hazard ratio 
0·41, 95% CI 0·21–0·80; p<0·0001).
Interpretation Low plasma troponin concentrations identify two-thirds of patients at very low risk of cardiac events 
who could be discharged from hospital. Implementation of this approach could substantially reduce hospital 
admissions and have major benefi ts for both patients and health-care providers.
Funding British Heart Foundation and Chief Scientist Offi  ce (Scotland).
Copyright © Shah et al. Open Access article distributed under the terms of CC BY-NC-ND.
 Introduction
Chest pain is a common cause of hospital admission 
worldwide and is a major burden on health-care 
resources.1 In the UK, chest pain is responsible for 
roughly 1 million visits to emergency departments each 
year.2 Although many of these patients might be suitable 
for direct discharge from the emergency department,3 
current care pathways are unable to rule out myocardial 
infarction at presentation, and guidelines recommend 
serial troponin tests requiring hospital admission in 
most patients.4 Because most of these patients do not 
have myocardial infarction, this approach leads to a large 
number of potentially avoidable hospital admissions.2,5,6
High-sensitivity cardiac troponin assays with high 
precision at very low concentrations enable accurate 
quantifi cation of troponin in most healthy people.7,8 
These assays could transform the assessment of patients 
with chest pain through the development of safe and 
eff ective strategies to exclude myocardial infarction in 
the emergency department.9 Although international 
guidelines10 recommend that cardiac troponin concen-
trations above the 99th centile be used for the diagnosis 
of myocardial infarction, some studies suggest that 
patients with undetectable troponin concentrations are 
at low risk.10–15
In a prospective study of the use of a high-sensitivity 
cardiac troponin I assay, we aimed to defi ne a threshold 
that identifi es patients with suspected acute coronary 
syndrome at presentation who are at low risk of myocardial 
infarction and potentially suitable for immediate discharge.
Methods
Study design and participants
For the derivation cohort, we prospectively identifi ed 
consecutive patients with suspected acute coronary 
syndrome presenting to emergency departments of 
secondary care hospitals (St John’s Hospital, Western 
General Hospital) and a tertiary care hospital (Royal 
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Infi rmary of Edinburgh) in the southeast of Scotland 
between June 1, 2013, and Jan 31, 2014, enrolled in the 
standard care arm of a stepped-wedge cluster randomised 
trial (ClinicalTrials.gov number NCT01852123). All 
patients who had cardiac troponin requested by the 
attending clinician and an electrocardiogram done were 
included. Patients were excluded if they had been 
admitted previously during the study period, were 
pregnant, or did not live in Scotland (appendix).
We then assessed the threshold in two independent 
validation cohorts (n=1434). The fi rst validation cohort 
included 1126 consecutively enrolled patients with 
suspected acute coronary syndrome presenting to 
the Royal Infi rmary of Edinburgh, Edinburgh, UK 
(appendix).12 The second included 308 consecutively 
enrolled patients from the UTROPIA study (ClinicalTrials.
gov number NCT02060760) who presented to Hennepin 
County Medical Center. The inclusion and exclusion 
criteria for the validation cohort were the same as for the 
deviation cohort.
The study was approved by the national research ethics 
committee, and in accordance with the Declaration of 
Helsinki.
Procedures
Attending clinicians reviewed all patients at 
presentation and included those with suspected acute 
coronary syndrome. The clinicians screened all patients 
for suspected acute coronary syndrome using an 
electronic form that was integrated into the clinical care 
pathway before measurement of plasma cardiac 
troponin I concen tration at presentation. Troponin 
testing was repeated 6 h or 12 h after the onset of 
symptoms at their discretion. All patients who met the 
inclusion criteria were assigned a study code and 
additional data from the electronic patient record were 
collected prospectively and linked in real time with a 
unique patient identifi er.
We collected baseline clinical characteristics and 
investigations from a standardised electronic patient 
record (TrakCare; InterSystems Corporation, Cambridge, 
MA, USA).11,12,16 Hyperlipidaemia and hypertension were 
defi ned as a history of the condition, or by the use of 
lipid-lowering or antihypertensive drugs, respectively. 
We calculated Global Registry of Acute Coronary Events 
(GRACE) risk scores and stratifi ed patients as low risk 
(<1% risk of in-hospital mortality) or intermediate–high 
risk (≥1% risk of in-hospital mortality).17
As standard of care, a sensitive cardiac troponin I assay 
(ARCHITECTSTAT troponin I assay; Abbott Laboratories, 
Abbott Park, IL, USA) was used for clinical decision 
making and the result declared to the patients’ clinicians. 
This assay has been validated.11,16 According to the 
manufacturer, the limit of detection is 10 ng/L and the 
upper reference limit (99th centile) of a normal reference 
population is 28 ng/L. The inter-assay coeffi  cient of 
variation was less than 10 % at 50 ng/L under local 
laboratory conditions and this concentration is used as 
the diagnostic threshold.
In parallel, a high-sensitivity assay (ARCHITECTSTAT 
high-sensitive troponin I assay; Abbott Laboratories) was 
used to remeasure cardiac troponin I concentrations on 
plasma excess to clinical requirements but the results were 
not reported on the health record systems or communicated 
to clinicians responsible for patients’ care. This assay has a 
limit of detection of 1·2 ng/L, and an upper reference limit 
(99th centile) of 34 ng/L in men and 16 ng/L in women.12,18 
It has a coeffi  cient of variation of 23% at the limit of 
detection (1·2 ng/L) and less than 10% at 6 ng/L.19,20 Assay 
precision was further evaluated across all laboratories 
under routine working conditions at regular intervals 
during the study by the independent United Kingdom 
National External Quality Assurance Scheme for cardiac 
biomarkers (Glasgow), which reported that the 
interlaboratory coeffi  cient of variation was 12·6% at 
3·5 ng/L across 33 instruments (appendix).
All patients with evidence of myocardial necrosis 
(troponin concentration >99th centile using sex-specifi c 
upper reference limit on presentation or subsequent 
testing) were identifi ed. Two investigators (AS, AA) 
See Online for appendix
Research in context
Evidence before this study
Patients with suspected acute coronary syndrome are admitted to 
hospital for serial cardiac troponin testing to rule out myocardial 
infarction at the 99th centile upper limit. Cohort studies and a 
recent systematic review and meta-analysis suggest that patients 
with undetectable plasma troponin concentrations at 
presentation are at low risk of myocardial infarction. However, the 
optimal approach and threshold of cardiac troponin to identify 
low-risk patients who would be suitable for immediate discharge 
is unknown. 
Added value of this study
We prospectively and systematically assessed a range of 
troponin concentrations using a high-sensitivity cardiac 
troponin I assay in consecutive unselected patients with 
suspected acute coronary syndrome across diff erent health-care 
settings. We established a threshold (<5 ng/L) that identifi ed a 
large proportion of patients at very low risk of cardiac events 
who were admitted to hospital but could have been safely 
discharged.
Implications of all the available evidence
Low plasma cardiac troponin I concentrations at presentation 
can enable the immediate and safe discharge of up to 
two-thirds of patients with suspected acute coronary 
syndrome. This approach could have major benefi ts for both 
patients and health-care providers. 
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independently reviewed all clinical information, including 
non-invasive and invasive investigations, and outcomes 
from presentation to 30 days. Patients were classifi ed as 
having type 1 or type 2 myocardial infarction, or having 
myocardial injury according to the universal defi nition of 
myocardial infarction.10,21 Type 1 myocardial infarction 
was defi ned as myocardial necrosis at an isolated 
presentation with suspected acute coronary syndrome 
with chest pain or evidence of myocardial ischaemia on 
an electrocardiogram. Patients with symptoms or signs of 
myocardial ischaemia due to increased oxygen demand 
or decreased supply (eg, tachyarrhythmia, hypotension, 
or anaemia) and myocardial necrosis were classifi ed as 
type 2 myocardial infarction. Myocardial injury was 
defi ned as evidence of myocardial necrosis in the absence 
of any clinical features of myocardial ischaemia. Any 
discrepancies were resolved by the adjudication of a third 
independent reviewer (NLM). Index myocardial infarction 
was defi ned as any type 1 myocardial infarction arising 
during the fi rst clinical episode. Agreement for an 
adjudicated diagnosis of type 1 myocardial infarction was 
excellent (κ 0·83, 95% CI 0·80–0·86).
We used regional and national registries to ensure that 
follow-up was complete for the entire study population. 
TrakCare (InterSystems; Cambridge, MA, USA) is a 
regional electronic patient record system, which provides 
data on all hospital admissions to both tertiary or 
secondary care hospitals in southeast Scotland. When 
assessing readmissions with myocardial infarction, all 
patients were re-adjudicated and classifi ed after review of 
all clinical notes and investigations, and according to the 
same criteria used for their index admission. All 
in-hospital and community deaths are recorded in a 
comprehensive national database, the General Register 
of Scotland. Cardiac death was defi ned as any death due 
to myocardial infarction, arrhythmia, or heart failure. 
Cardiac death was defi ned with ICD-10 codes I20–25, 
I34–37, I42, I43, I46, and I48–51.
Outcomes
The primary outcome was a composite of index type 1 
myocardial infarction, or type 1 myocardial infarction or 
cardiac death at 30 days. The secondary outcome was 
1-year survival from myocardial infarction or cardiac 
death following the index presentation. 
Statistical analysis
We established the negative predictive values for the 
primary outcome across a range of troponin concentrations 
starting at 1 ng/L. Patients with ST-segment elevation 
myocardial infarction and troponin concentrations above 
the 99th centile on presentation were not included in this 
analysis. Previous analyses of high-sensitivity cardiac 
troponin T assay have used a threshold based on the 
lowest detectable concentration. However, the precision of 
the high-sensitivity cardiac troponin I assay at low 
concentrations is suffi  cient to enable the assessment of a 
All patients (n=4870) <99th centile at 
presentation* (n=3799)
Age (years) 64 (16) 62 (16)
Women 2061 (43%) 1580 (42%)
Presenting complaint n=4870 n=3799
Chest pain 4043 (83%) 3251 (86%)
Dyspnoea 269 (6%) 141 (4%)
Palpitations 127 (3%) 102 (3%)
Syncope 181 (4%) 134 (4%)
Other 250 (5%) 171 (5%)
≤2 h since onset of chest pain 657/4043 (16%) 482/3251 (15%)
Medical history n=4277 n=3317
Diabetes 669 (16%) 513 (16%)
Hypertension 1393 (33%) 1033 (31%)
Hyperlipidaemia 1123 (27%) 870 (26%)
Cerebrovascular accident 337 (8%) 236 (7%)
Myocardial infarction 796 (19%) 606 (18%)
Ischaemic heart disease 1391 (33%) 1058 (32%)
Previous revascularisation n=4269 n=3289
Percutaneous coronary intervention 447 (11%) 360 (11%)
Coronary artery bypass graft 245 (6%) 178 (5%)
Current drugs† n=3004 n=2370
Statin 1124 (38%) 881 (37%)
Aspirin 926 (32%) 720 (30%)
Clopidogrel 336 (11%) 248 (10%)
ACE inhibitor or ARB 962 (33%) 745 (31%)
β blockers 772 (26%) 584 (25%)
Oral anticoagulant 211 (7%) 159 (7%)
Cardiac troponin concentrations
At presentation (ng/L) 5 (2–19) 5 (3–11)
Peak (ng/L) 6 (2–26) 4 (2–8)
Electrocardiograph results n=4244 n=3279
Bundle branch block 278 (7%) 164 (5%)
ST-segment elevation 143 (3%) 93 (3%)
ST-segment depression 302 (7%) 153 (5%)
T-wave inversion 515 (13%) 341 (10%)
Heart rate (beats per min) 82 (23) 80 (22)
Systolic blood pressure (mm Hg) 138 (26) 138 (25)
Adjudicated diagnosis n=4870 n=3799
Non-ST-elevation type 1 myocardial infarction 651 (13%) 132 (3%)
ST-elevation type 1 myocardial infarction 131 (3%) 0 (0%)
Type 2 myocardial infarction 173 (4%) 33 (1%)
Myocardial injury 301 (6%) 21 (1%)
Admitted to hospital 2978 (61%) 2015 (53%)
Outcome at 30 days n=4870 n=3799
Readmission with myocardial infarction 32 (1%) 13 (0%)
Cardiac death 75 (2%) 13 (0%)
Index type 1 myocardial infarction, readmission 
with type 1 myocardial infarction or cardiac death
814 (17%) 145 (4%)
Data are mean (SD), n (%), or median (IQR). ACE=angiotensin converting enzyme. ARB=angiotensin receptor blocker. 
*Excludes patients presenting with ST-segment elevation myocardial infarction. †Drugs patients were already taking 
at presentation.
Table 1: Baseline characteristics of the derivation cohort
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range of thresholds.10–15 As such, we selected a threshold on 
the basis of clinical need rather than assay performance. 
The trial steering committee prespecifi ed that the cardiac 
troponin threshold on presentation should achieve a 
negative predictive value of at least 99·5% for the primary 
outcome. In sample size calculations, we estimated that 
3500 patients would enable us to estimate a negative 
predictive value of 99·5% with a 95% CI of 99·2–99·7, 
and that we had 92% power for an α of 0·05 to test the 
null hypothesis that the negative predictive value was less 
than 99%.
We assessed the proportion of patients with troponin 
concentrations below each threshold who reached the 
primary outcome. We did subgroup analyses to estimate 
the negative predictive value, stratifying by age, sex, 
duration of symptoms, cardiovascular risk factors, 
history of cardiovascular disease, and presence of 
myocardial ischaemia on the presenting electro-
cardiogram. We expected the negative predictive value to 
be close to 100%; therefore, we estimated the proportion 
by sampling from a binomial likelihood with a Jeff rey’s 
prior (β distribution shape parameters both equal to 0·5) 
because intervals produced with this approach have 
good coverage for proportions close to 0 or 1.22 We 
compared survival free from myocardial infarction 
or cardiac death between patients with troponin 
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Figure 1: Cardiac troponin I concentration at presentation and risk of myocardial infarction
(A) Negative predictive value of a range of troponin I concentrations at presentation for the composite outcome of index myocardial infarction, and myocardial infarction 
or cardiac death at 30 days. (B) Cumulative proportion of patients with suspected acute coronary syndrome with troponin concentrations below each threshold.
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concentrations above and below the threshold using Cox 
proportional hazard models adjusted for age and sex. 
For the validation cohort, we estimated the proportion of 
patients with troponin concentrations below the 
threshold determined in the derivation cohort who 
reached the primary outcome, using the same method. 
We did the analyses with R (version 3.2.2).
Role of the funding source
The funder had no role in study design, data collection, 
analysis, or interpretation, or the writing of the report. 
The trial steering committee and NLM were responsible 
for the decision to submit the report for publication.
Results
We enrolled 6304 patients with suspected acute coronary 
syndrome: 4870 in the derivation cohort (table 1, appendix), 
1126 in the internal validation cohort (appendix), and 
308 in the external validation cohort (appendix).
In the derivation cohort, most patients presented with 
chest pain that began more than 2 h before troponin 
testing (table 1, appendix p 10). The median time from 
arrival in the emergency department to blood sampling 
for measurement of cardiac troponin was 54 min 
(IQR 33–85; appendix p 11). Repeat testing was done for 
1608 (42%) of 3799 patients with troponin concentrations 
at presentation of below the 99th centile. Troponin 
concentrations were above the limit of detection in 4304 
(88%) of 4870 patients and were above the 99th centile in 
1253 (26%) of 4870 patients, with 782 (16%) judged to 
have type 1 myocardial infarction and 173 (4%) to have 
type 2 myocardial infarction. A further 301 (6%) of 
4870 patients were classifi ed as having myocardial injury. 
At 30 days, 32 (1%) patients re-presented with myocardial 
infarction, and 75 (2%) died from cardiac causes.
In the derivation cohort, low plasma troponin con-
centrations at presentation gave excellent negative 
predictive value for the composite endpoint of index type 1 
myocardial infarction, or type 1 myocardial infarction or 
cardiac death at 30 days. A troponin concentration <5 ng/L 
was present in 2311 (61%) of 3799 patients below the 
99th centile at presentation, giving a negative predictive 
value of 99·6% (95% CI 99·3–99·8; fi gure 1, appendix 
p 4). The negative predictive value decreased at higher 
troponin concentrations and was less than 99·5% at 
concentrations of 5 ng/L or more.
The negative predictive value of a troponin concen-
tration less than 5 ng/L was similar in men and women 
and when stratifi ed by age, cardiovascular risk factors, 
previous cardiovascular disease, or the presence of 
myocardial ischaemia on the presenting electro-
cardiograph (fi gure 2). In 2017 patients with a troponin 
concentration of less than 5 ng/L and an available 
electrocardiograph, 1833 (91%) had no evidence of 
ischaemia. The negative predictive value was similar 
across groups stratifi ed by GRACE risk score (low risk 
99·7%, 95% CI 99·4–100% vs intermediate–high risk 
98·4%, 97·0–99·7). The negative predictive value was 
lower in the 482 (15%) of 3251 patients who were tested 
for troponin within 2 h of the onset of chest pain 
(97·6%, 95% CI 95·8–99·2) than in the 2769 (85%) who 
had had chest pain for more than 2 h (99·8%, 95% CI 
99·6–100·0). In a post-hoc sensitivity analysis in which 
type 2 myocardial infarction and myocardial injury were 
incorporated into the primary outcome (a troponin 
concentration >99th centile irrespective of clinical 
presentation), a troponin concentration of less than 
5 ng/L gave a negative predictive value of 99·4% 
(95% CI 99·0–99·7).
In the two validation cohorts, a troponin concentration 
less than 5 ng/L was present in 470 (57%) of 829 and 
124 (54%) of 232 patients without myocardial infarction 
at presentation, and had a negative predictive value of 
99·3% (95% CI 98·5–99·9) and 99·8% (98·0–100·0), 
respectively. Overall troponin concentrations were less 
Figure 2: Negative predictive value of troponin concentrations <5 ng/L at presentation, stratifi ed by subgroups
For the composite outcome of index myocardial infarction, and myocardial infarction or cardiac death at 30 days. 
Dashed line is the prespecifi ed negative predictive value of 99·5%.
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than 5 ng/L in 594 patients (56%) with a negative 
predictive value of 99·4% (98·8–99·9). Across all 
derivation and validation cohorts, 12 (0·4%) of 
2905 patients with troponin concentrations less than 
5 ng/L at presentation met the primary endpoint 
(appendix pp 5–6).
In the derivation cohort, 2978 (61%) patients were 
admitted to hospital for further investigation (table 1). In 
the 2272 patients admitted to hospital who were not 
diagnosed with type 1 myocardial infarction, 1009 (44%) 
had troponin concentrations less than 5 ng/L at 
presentation and might have been suitable for immediate 
discharge.
In the derivation cohort, patients with troponin 
concentrations less than 5 ng/L at presentation, 
myocardial infarction or cardiac death were rare at a 
median follow-up of 427 days (IQR 371–489; fi gure 3). 
Compared with patients with peak troponin concentrations 
between 5 ng/L and the 99th centile (appendix p 7), 
patients with troponin concentrations of less than 5 ng/L 
at presentation were less likely to have myocardial 
infarction or cardiac death at 1 year (p=0·0001; table 2). 
This association persisted after adjustment for diff erences 
in age and sex (p<0·0001; table 2).
Discussion
In more than 6000 patients with suspected acute 
coronary syndrome, we have defi ned a cardiac troponin 
threshold at presentation that identifi es almost two-thirds 
of patients as being at very low risk of myocardial 
infarction or cardiac death, and who could potentially be 
safely discharged from the emergency department. 
Implementation of this approach would reduce avoidable 
hospital admission and have major benefi ts for both 
patients and health-care providers.
Our study has several strengths that distinguish it from 
previous studies. First, we prospectively identifi ed all 
consecutive unselected patients presenting to both 
secondary and tertiary care hospitals, including patients 
admitted out of hours. As such, we believe our fi ndings to 
be both representative and generalisable, and that this 
approach will be widely applicable across diff erent 
health-care settings. Second, our study population 
exceeded the combined number of patients in a 
meta-analysis,3 which enabled us to analyse clinically 
important subgroups, such as patients who present early 
or have previous cardiovascular disease. Third, we have 
systematically assessed a range of troponin concentrations 
to identify a threshold that maximised the proportion of 
patients to be safely discharged. Finally, we used an assay 
with the necessary precision under routine laboratory 
conditions to report troponin concentrations at this 
threshold and to use this approach to guide patient care.
One of the main limitations was that we did not test the 
implementation of this threshold in routine clinical 
practice. Although we determined the number of patients 
who could be safely discharged, whether clinicians can 
eff ectively implement this threshold in clinical practice 
and whether this will substantially improve rates of 
discharge, is unknown. Conversely, this threshold should 
not be implemented in isolation and without regard to 
appropriate clinical assessment. One in 200 patients still 
had an index or 30-day event and many had other evidence 
of myocardial ischaemia. Finally, we had no data about 
later investigations and treatments. Implementation of 
this threshold is expected to reduce health-care costs but 
these benefi ts might be lost if recurrent presentations or 
additional outpatient consultations increase.
Figure 3: Cumulative incidence of myocardial infarction or cardiac death in patients with troponin 
concentrations less than the 99th centile
Patients without index myocardial infarction were stratifi ed into two groups based on the troponin concentration 
at presentation. Compared to patients with troponin concentrations ≥5 ng/L, patients with troponin 
concentrations <5 ng/L were less likely to have a myocardial infarction or cardiac death at 1 year (0·6% vs 3·3%; 
hazard ratio 0·41, 95% CI 0·21–0·80; log-rank p<0·0001).
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1 year 6 (0·3%) 19 (1·3%) 0·21
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0·36
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Cardiac death
30 days 0 (0·0%) 6 (0·4%)
1 year 6 (0·3%) 32 (2·2%) 0·14
(0·06–0·31)
0·41
(0·17–0·98)
Myocardial infarction or cardiac death
30 days 0 (0·0%) 12 (0·8%)
1 year 12 (0·6%) 48 (3·3%) 0·17
(0·09–0·31)
0·41
(0·21–0·80)
Data are n (%) unless stated otherwise. The hazard ratios are derived from a Cox regression model using all follow-up 
data. The median follow up was 427 days (IQR 371–489 days). 
Table 2: Subsequent myocardial infarction or cardiac death in patients with troponin concentrations 
below the 99th centile in the derivation cohort
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A troponin concentration of less than 5 ng/L met our 
prespecifi ed criteria for a negative predictive value of at 
least 99·5%. At this threshold, almost two-thirds of 
patients with suspected acute coronary syndrome could 
have been discharged with very few cardiac events. 
Indeed, implementation of this threshold could double 
the number of patients discharged directly from the 
emergency department. Lower thresholds did not 
improve the negative predictive value, and would 
identify fewer patients suitable for discharge. 
Increasing the threshold to less than 6 ng/L would 
identify an additional 6% of patients suitable for 
discharge, but would double the number of adverse 
events. Moreover, we have internally and externally 
validated this threshold, and a troponin concentration 
less than 5 ng/L seems to be the best threshold for our 
study populations.
The negative predictive value of our approach was 
99·6% across the entire study population, and was 
similar for men and women, between age groups, and in 
patients with previous cardiovascular disease. The use of 
risk scores to stratify patients with suspected acute 
coronary syndrome is common, but few scores have been 
developed or validated in this population, in which most 
patients did not have myocardial infarction. Stratifi cation 
by GRACE score did not signifi cantly improve the 
negative predictive value. The negative predictive value 
remained high in patients with a high pre-test probability 
of myocardial infarction, suggesting that this approach is 
probably valid even in higher risk populations. The only 
factor that seemed to aff ect the negative predictive value 
was the time from onset of chest pain to troponin testing. 
The negative predictive value of patients presenting 
within 2 h of chest pain was 97·6% but such patients 
were a small proportion of the overall population and 
could be addressed by repeat testing.
Of the 2905 patients with troponin concentrations of 
less than 5 ng/L at presentation, only 12 had an adverse 
event, of whom ten had an index myocardial infarction 
with fi ve having clear diagnostic evidence of myocardial 
ischaemia on the presenting electrocardiograph. 
Two further patients were in cardiac arrest at presen-
tation and did not survive. We included all consecutive 
patients without selection to make our safety estimates 
conservative. However, most of these adverse events 
would have been identifi ed at presentation and therefore 
these patients would probably not have been discharged 
from hospital. This fi nding also shows the importance 
of not applying this threshold in isolation and that all 
available information should be used for clinical 
decision making.
Our observations complement previous studies of the 
use of cardiac troponins to triage patients with suspected 
acute coronary syndrome in emergency departments. The 
limit of detection and the limit of blank of a high-sensitivity 
cardiac troponin T assay both show promise for the 
assessment of patients at presentation.10–12 These studies 
were included in a systematic review and meta-analysis5 
showing that cardiac troponin T concentrations below the 
limit of detection had a false negative rate of 1·5% and 
identifi ed 25% of patients as low risk. However, half of the 
studies used a contemporary troponin assay as a reference 
and would have missed smaller myocardial infarctions 
that could only be detected with a high-sensitivity assay, 
which will infl ate the negative predictive value. In our 
analysis, we judged the fi nal diagnosis using a high-
sensitivity assay to ensure robust case ascertainment. 
Unlike previous studies of the cardiac troponin T assay, 
our analysis was the fi rst to use a high-sensitivity cardiac 
troponin I assay, which has greater precision and 
reproducibility at low concentrations and at the proposed 
threshold. This will ensure the application of this approach 
is consistent across sites, analysers, and reagent batches: a 
prerequisite for use in clinical practice. Furthermore, use 
of cardiac troponin I at our threshold identifi es 
two-to-three-times more low-risk patients than do previous 
approaches,10–12,23 which would avoid the need for repeat 
testing in most patients, or the incorporation of clinical 
risk scores used in accelerated diagnostic pathways.24–26 
Studies are needed assess the clinical and cost-
eff ectiveness of our approach in routine clinical practice.
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